Biocon receives regulatory approval for biosimilar product, trastuzumab
Mylan Inc. today announced that its partner Biocon has received approval for a Mylan-Biocon trastuzumab product from the Drug Controller General of India. This is the first regulatory approval for a Mylan-Biocon developed biosimilar product.